Insulet Corporation Announces Pricing of Secondary Public Offering
J.P. Morgan Securities Inc. and Merrill Lynch, Pierce, Fenner & SmithIncorporated are acting as joint book-running managers, and Leerink Swann LLC,Thomas Weisel Partners LLC and Canaccord Adams Inc. are acting as co-managersfor the offering.
A registration statement relating to these securities has been filed withthe Securities and Exchange Commission and has become effective. This pressrelease shall not constitute an offer to sell or the solicitation of an offerto buy, nor shall there be any sale of these securities in any state orjurisdiction in which such offer, solicitation or sale would be unlawful priorto registration or qualification under the securities laws of any such stateor jurisdiction. Any offer or sale will be made only by means of the writtenprospectus forming part of the effective registration statement.
A copy of the prospectus relating to the offering may be obtained bycontacting one of the following:
About Insulet Corporation
Insulet Corporation is an innovative medical device company dedicated toimproving the lives of people with diabetes. The Company's OmniPod InsulinManagement System is a revolutionary, discreet and easy-to-use insulininfusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks toexpand the use of continuous subcutaneous insulin infusion (CSII) therapyamong people with insulin-dependent diabetes. Founded in 2000, Insulet isbased in Bedford, MA.
For more information about Insulet Corporation and the OmniPod System,please visit our website at www.insulet.com.J.P. Morgan Securities Inc., National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by calling (718) 242-8002. Merrill Lynch, Pierce, Fenner & Smith Incorporated, World Financial Center, 250 Vesey Street, New York, NY 10080 or by calling (212) 449-1000.
SOURCE Insulet Corporation
You May Also Like